Ligand buys AB Initio Biotherapeutics in a $12m cash transaction
Category: #health  By Mateen Dalal  Date: 2019-07-25
  • share
  • Twitter
  • Facebook
  • LinkedIn

Ligand buys AB Initio Biotherapeutics in a $12m cash transaction

Ligand is eligible to receive royalties and milestones depending on potential future sales

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company focused on acquiring and developing technology that help pharmaceutical companies to discover and develop medicines, recently announced that that it inked an agreement to acquire Ab Initio Biotherapeutics for an amount of $12 million in cash.

An antigen-discovery company, Ab Initio is privately held and based in South San Francisco, California. The preparation and design of antigen are the first few steps required to discover therapeutic antibodies. Certain antibodies are difficult and need a special approach in order to design, prepare and deliver an antigen to ensure the successful discovery of an antibody drug candidate.

The transaction is expected to have a minimum impact on the cost structure of Ligand in the future.

Ab Initio provides a patented antigen tech to Ligand that happens to be synergistic with its discovery platform, OmniAB therapeutic antibody. The new technology will be providing the potential and current new partners of Ligand enhanced capabilities to discover therapeutic antibodies against cellular targets that are difficult to access.

Ligand’s Chief Executive Officer, John Higgins commented that the technology by Ab Initio is extremely complementary to the company’s OmniAb platform. A necessary step in the discovery of antibody will be the antigen generation with some complex targets, owing to initial work like antigen design & preparation being difficult.

Ligand will be able to meet its partner’s needs by bolting on the proprietary antigen technology. Ligand will be providing an antibody discovery platform that offers decent value to their current partners, Higgins added.

Kenneth Lin, co-founder and CEO of Ab Initio said that the company aims to develop prize-winning scientific breakthroughs by having created antigens that ensure antibody discovery against the therapeutics targets. OmniAb is a natural fit that will let the technology from Ab Initio to impact a broader industry along with new discovery programs.

 

Source Credit- https://investor.ligand.com/press-releases/detail/389/ligand-acquires-ab-initio-biotherapeutics-an

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Dermtech signs a commercial & medicare advantage coverage agreement
Dermtech signs a commercial & medicare advantage coverage agreement
By Mateen Dalal

DermTech Inc., a San Diego based biotechnology company that is involved in precision dermatology, has recently announced signing a contract with a regional health plan to develop its gene expression based PLA (Pigmented Lesion Assay) for prior detect...

CoImmune Inc. inks all-stock merger deal with Formula Pharmaceutical
CoImmune Inc. inks all-stock merger deal with Formula Pharmaceutical
By Mateen Dalal

The merger will bring two therapeutic immune-oncology platforms together Focus shall be placed over Phase 1 and Phase 2 trials of CAR-CIK and CMN-001 respectively U.S.-based bioscience firm CoImmune, Inc., announces partnership with Formula Phar...

Adverum reviews recent business progress and unveils its 2020 outlook
Adverum reviews recent business progress and unveils its 2020 outlook
By Mateen Dalal

Adverum Biotechnologies, a California based biotech company, has reportedly announced that it has examined its recent business & development progress. The company has also unveiled its outlook for 2020. Leone Patterson, president and chief execu...